Since functional validation of ATR's involvement in GBM radioresistance with the ATR inhibitor AZD-6738 provided very convincing radiosensitization of GBM cells in vitro, and similar evidence has also been provided by others [46], ATR inhibition in combined modality GBM radiotherapy certainly deserves more in-depth preclinical investigation. This evidence concerns the gene ATR and glioblastoma.